Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.62 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.62 |
| ▸ | FAAH | O00519 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28869329 | 0.94 | MAPT (1.00) | MAPTSMN1; SMN2BLMKMT2ACYP2D6 | |
| SCHEMBL20236897 | 0.88 | MAPT (0.88) | MAPTSMN1; SMN2BLMKMT2ACYP2D6 | |
| SCHEMBL3949152 | 0.88 | MAPT (0.88) | MAPTSMN1; SMN2BLMKMT2ACYP2D6 | |
| SCHEMBL8361624 | 0.87 | SMN1; SMN2 (0.97) | MAPTSMN1; SMN2BLMKMT2ACYP2D6 | |
| SCHEMBL4559572 | 0.87 | SMN1; SMN2 (0.91) | MAPTSMN1; SMN2BLMKMT2ACYP2D6 | |
| SCHEMBL5195426 | 0.86 | SMN1; SMN2 (1.00) | MAPTSMN1; SMN2BLMKMT2ACYP2D6 | |
| SCHEMBL13234920 | 0.85 | MAPT (0.87) | MAPTSMN1; SMN2BLMKMT2ALMNA | |
| SCHEMBL20236190 | 0.84 | MAPT (0.80) | MAPTSMN1; SMN2BLMKMT2ACYP2D6 | |
| SCHEMBL20236800 | 0.84 | MAPT (0.80) | MAPTSMN1; SMN2BLMKMT2ACYP2D6 | |
| SCHEMBL5458965 | 0.83 | MAPT (0.79) | MAPTSMN1; SMN2BLMKMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | MAPT 3204/4885SMN1; SMN2 4060/4885BLM 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.